Pharma BD Deal Intelligence

Sanofi SA / Sino Biopharmaceutical Ltd.

2026 · Licensing/Option · $1.5B · Pending

A $1.53B licensing deal that hands Sanofi global rights to rovadicitinib, a first-in-class oral JAK/ROCK inhibitor just approved in China for myelofibrosis. Sanofi is betting the drug's anti-fibrotic profile extends into chronic graft-versus-host disease alongside its existing Rezurock franchise, though the agreement remains unclosed pending regulatory clearance.

CALLED IT — OFF BY 21
Full analysis, sources & comparables →

The coverage arc

Mar 04, 2026 BioPharma Dive Neutral

Drugs from China are reshaping biotech. Track the licensing deals here. The database of cross-border China licensing deals captures Sanofi's $1.53 billion deal…

Mar 04, 2026 Pharmaceutical Technology Bullish

Sanofi bets on Sino Biopharm rovadicitinib in $1.5B licensing deal for first-in-class JAK/ROCK inhibitor.

Mar 12, 2026 Baker McKenzie Neutral

Baker McKenzie advised Sino Biopharm on the up to US$1.53 billion exclusive license agreement with Sanofi for rovadicitinib, a global first-in-class oral…

Source summaries from our enrichment pipeline; follow links for originals.

All 10 sources with sentiment breakdown →

Sanofi signed a global exclusive license agreement with Sino Biopharmaceutical's Chia Tai Tianqing subsidiary, announced March 4, 2026, for rovadicitinib (China brand Anxu), a first-in-class oral dual JAK/ROCK inhibitor delivering combined anti-inflammatory and anti-fibrotic effects. Sanofi pays $135M upfront plus up to $1.395B in development, regulatory and sales milestones and up to double-digit tiered royalties (up to $1.53B total) for worldwide rights to develop, manufacture and commercialize the asset. Rovadicitinib won its first China approval in February 2026 for intermediate-2/high-risk myelofibrosis (PMF/PPV-MF/PET-MF); Sanofi intends to develop it for chronic graft-versus-host disease (Phase III ongoing in China, Phase II cleared in the US), positioning it within its transplant franchise alongside Rezurock (belumosudil). The agreement's effectiveness is subject to customary closing conditions including regulatory clearances, so the transaction was signed but not yet closed as of the review.

Key facts

Disease & market context

Myelofibrosis

3K US cases/yr · $3.0B US MPN Rx Market

Disease Overview

Myelofibrosis is a rare bone marrow cancer characterized by fibrosis and cytopenias. JAK inhibitors (ruxolitinib, fedratinib) are current SOC but have limited disease-modifying effect. Rovadicitinib's dual JAK/ROCK mechanism offers potential anti-fibrotic benefit.

Competitive Landscape

Rovadicitinib (Anxu) approved in China for intermediate-2/high-risk myelofibrosis. Dual JAK/ROCK mechanism differentiates from pure JAK inhibitors. Competes with ruxolitinib (Jakafi), fedratinib (Inrebic), pacritinib (Vonjo), momelotinib (Ojjaara).

Myelofibrosis (Ex-China Development)

Competitive Landscape

Rovadicitinib is a dual JAK/ROCK inhibitor for myelofibrosis (MF), entering a MOA-fragmented but JAK-dominated market. Selective JAK inhibitors: ruxolitinib (Jakafi, Incyte/Novartis) is the standard of care and category anchor; Incyte reported 2023 Jakafi net product revenues of approximately $2.77B. Fedratinib (Inrebic, BMS) is FDA-approved 2019 for intermediate-2/high-risk MF, including post-ruxolitinib. Pacritinib (Vonjo, Sobi/CTI BioPharma) received accelerated approval in 2022 for MF with severe thrombocytopenia (<50k platelets), a cytopenic niche. Momelotinib (Ojjaara, GSK) gained FDA approval September 2023 for MF with anemia, differentiated via ACVR1 inhibition. BET inhibitor combination: pelabresib (CPI-0610, Novartis, Phase 3 MANIFEST-2 readout) combined with ruxolitinib targets frontline intensification. Anti-fibrotic/imetelstat: imetelstat (Rytelo, Geron), a telomerase inhibitor approved in lower-risk MDS June 2024, has Phase 3 IMpactMF ongoing in relapsed/refractory MF. Rovadicitinib's ROCK contribution targets bone-marrow fibrosis directly; commercial threat depends on whether it shows spleen volume reduction and anemia benefit superior to momelotinib and a ruxolitinib + pelabresib future SOC. Ex-China positioning places it against a crowded late-stage field where differentiation in cytopenic or anemic subpopulations will drive share.

Deal timeline

Related deals — scored

DealYearValueOutcome
Sanofi SA / Sino Biopharmaceutical Ltd. (this deal)2026$1.5B64
Sanofi SA / Regeneron Pharmaceuticals, Inc.2007$1.0B97
Sanofi SA / Synthelabo S.A.1998$11.0B84
Sanofi SA / Genzyme Corporation2011$20.1B84
Sanofi SA / Amunix Pharmaceuticals Inc.2021$1.2B76
Sanofi SA / Genzyme Corporation2010$18.5B75
Sanofi SA / Translate Bio Inc.2018$805M73

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →